Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CERCA
MCID: CRV035
MIFTS: 76

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cervical Cancer

About this section

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 56 12 74 73 36 54 42 3 15 62 71
Uterine Cervical Neoplasms 6 43
Uterine Cervical Neoplasm 12 71
Cervical Cancer, Somatic 56 13
Cervix Cancer 12 73
Neoplasm of Uterine Cervix 12
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 39
Malignant Tumor of Cervix 71
Uterine Cervical Cancer 73
Cervix Uteri Cancer 12
Neoplasms Cervical 54
Cervical Neoplasm 12
Cervix Carcinoma 71
Cervical Cancers 15
Cerca 73

Characteristics:

HPO:

31
cervical cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4362
OMIM 56 603956
KEGG 36 H00030
ICD9CM 34 180 180.9
MeSH 43 D002583
NCIt 49 C2940 C9311
SNOMED-CT 67 93752005
ICD10 32 C53 C53.9
SNOMED-CT via HPO 68 108369006 124975008 363346000
UMLS 71 C0007847 C0007873 C0302592 more
Sources

Summaries for Cervical Cancer

About this section
MedlinePlus : 42 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasms, is related to cervix carcinoma and squamous cell carcinoma, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Bethanechol and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and breast, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix connects the vagina (birth canal) to the upper part of the uterus. The uterus (or womb) is where a baby grows when a woman is pregnant. All women are at risk for cervical cancer. It occurs most often in women over age 30. Human papillomavirus (HPV) is the main cause of cervical cancer. HPV is a common virus that is passed from one person to another during sex. At least half of sexually active people will have HPV at some point in their lives, but few women will get cervical cancer. Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

KEGG : 36 Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types, particularly types 16, 18, 33 and 42. Experimental studies show that the E6 and E7 genes of these high risk HPVs are oncogenes that deregulate key cell cycle controls. The E6 and E7 oncoproteins bind respectively to the p53 and Retinoblastoma (Rb) tumor suppressor proteins, which are involved in the regulation of growth control. The abnormalities in other cellular genes found in cervical cancer, including mutations in ras family of genes, and amplification in EGFR and ERBB2, may also play an important role in carcinogenesis and the aggressiveness of cervical tumors, although to date the role of most of these genetic abnormalities does not appear to be as important as the role of HPV.

UniProtKB/Swiss-Prot : 73 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 62 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer. The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 74 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

More information from OMIM: 603956
Sources

Related Diseases for Cervical Cancer

About this section

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 900)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 34.3 TP53 STAT3 MIR214 FGFR3
2 squamous cell carcinoma 33.4 TUG1 TP53 STAT3 SMAD4 PTEN PIK3CA
3 papilloma 33.3 TP53 PTEN FGFR3 CCND1
4 adenocarcinoma 33.2 TP53 STAT3 SMAD4 PTEN PIK3CA HRAS
5 endometrial cancer 33.1 TUG1 TP53 STAT3 SMAD4 PTEN PIK3CA
6 in situ carcinoma 32.9 TP53 PTEN HRAS ERBB2 CCND1
7 ovarian cancer 32.9 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
8 cervical squamous cell carcinoma 32.8 TP53 STAT3 PIK3CA CTNNB1
9 colorectal cancer 32.8 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
10 lung cancer 32.7 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
11 adenosquamous carcinoma 32.6 TP53 SMAD4 PTEN PIK3CA
12 squamous cell papilloma 32.6 TP53 HRAS
13 bladder cancer 32.6 TUG1 TP53 PVT1 PTEN PIK3CA MIR214
14 b-cell lymphoma 32.6 TUG1 TP53 STAT3 PVT1 MIR21 HOTAIR
15 breast cancer 32.5 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
16 esophageal cancer 32.5 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
17 lung cancer susceptibility 3 32.4 TUG1 TP53 STAT3 SMAD4 PTEN PIK3CA
18 cervical adenocarcinoma 32.4 TP53 PTEN ERBB2
19 gastric cancer 32.3 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
20 prostate cancer 32.3 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
21 pancreatic cancer 32.3 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
22 hepatocellular carcinoma 32.3 TUG1 TP53 STAT3 SMAD4 PVT1 PTEN
23 nasopharyngeal carcinoma 32.3 TP53 STAT3 SMAD4 PVT1 PTEN PIK3CA
24 melanoma 32.2 TP53 PVT1 PTEN PIK3CA MTOR HRAS
25 leukemia, acute myeloid 32.2 TUG1 TP53 STAT3 PTEN MTOR MIR21
26 glioblastoma multiforme 32.1 TP53 STAT3 PTEN PIK3CA MTOR MIR21
27 oropharynx cancer 31.9 TP53 PTEN PIK3CA HRAS ERBB2 CCND1
28 squamous cell carcinoma, head and neck 31.9 TP53 STAT3 SMAD4 PTEN PIK3CA NFE2L2
29 leukemia, chronic lymphocytic 31.9 TP53 STAT3 PTEN MIR214 MIR21 HRAS
30 anus cancer 31.9 TP53 PIK3CA HRAS
31 leukemia 31.9 TP53 STAT3 HRAS HOTAIR GAS5 ERBB2
32 lymphoma 31.9 TP53 STAT3 PVT1 PIK3CA GAS5 CCND1
33 endometrial adenocarcinoma 31.9 TP53 PTEN ERBB2 CTNNB1 CCND1
34 myeloma, multiple 31.8 TUG1 TP53 STAT3 PVT1 PTEN MTOR
35 penile cancer 31.8 TP53 PTEN PIK3CA HRAS CCND1
36 ureteral obstruction 31.8 TP53 NFE2L2 CTNNB1
37 kidney cancer 31.8 TP53 PVT1 PTEN PIK3CA NFE2L2 MTOR
38 serous cystadenocarcinoma 31.7 TP53 PTEN PIK3CA HRAS ERBB2
39 bladder urothelial carcinoma 31.7 TUG1 TP53 PVT1 PTEN PIK3CA NFE2L2
40 thyroid carcinoma 31.7 TP53 PTEN PIK3CA HRAS CTNNB1
41 ovarian disease 31.7 TP53 STAT3 PTEN PIK3CA MIR21 HRAS
42 osteogenic sarcoma 31.7 TUG1 TP53 PVT1 HOTAIR GAS5
43 retinitis pigmentosa 11 31.7 TP53 PVT1 PTEN HRAS HOTAIR
44 colon adenocarcinoma 31.7 TP53 SMAD4 PTEN PIK3CA MIR21 ERBB2
45 carcinosarcoma 31.6 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
46 lynch syndrome 31.6 TP53 SMAD4 PTEN PIK3CA HRAS FGFR3
47 kaposi sarcoma 31.6 TP53 STAT3 MTOR CCND1
48 diffuse large b-cell lymphoma 31.6 TP53 STAT3 PTEN MTOR MIR21 HOTAIR
49 renal cell carcinoma, nonpapillary 31.6 TUG1 TP53 STAT3 PVT1 PTEN PIK3CA
50 pancreatic adenocarcinoma 31.6 TP53 STAT3 SMAD4 PTEN PIK3CA MIR21

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer
Sources

Symptoms & Phenotypes for Cervical Cancer

About this section

Human phenotypes related to Cervical Cancer:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm 31 HP:0002664
2 abnormality of the cervical spine 31 HP:0003319

Clinical features from OMIM:

603956

UMLS symptoms related to Cervical Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 CTNNB1 ERBB2 FGFR3 HRAS MTOR PTEN
2 Decreased cell migration GR00055-A-1 9.72 CTNNB1 FGFR3 HRAS MTOR PIK3CA
3 Decreased viability in esophageal squamous lineage GR00235-A 9.7 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
4 Reduced mammosphere formation GR00396-S 9.23 CCND1 GNAS HRAS MTOR NFE2L2 PTEN
5 Decreased sensitivity to paclitaxel GR00112-A-0 9.16 PTEN SMAD4

MGI Mouse Phenotypes related to Cervical Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
2 cardiovascular system MP:0005385 10.36 CCND1 CTNNB1 ERBB2 GNAS HRAS MTOR
3 cellular MP:0005384 10.35 CCND1 CTNNB1 ERBB2 FGFR3 GNAS MTOR
4 growth/size/body region MP:0005378 10.34 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.32 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
6 endocrine/exocrine gland MP:0005379 10.28 CCND1 CTNNB1 ERBB2 GNAS HRAS MTOR
7 craniofacial MP:0005382 10.27 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
8 digestive/alimentary MP:0005381 10.26 CCND1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
9 integument MP:0010771 10.26 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
10 immune system MP:0005387 10.24 CCND1 CTNNB1 FGFR3 GNAS MTOR NFE2L2
11 embryo MP:0005380 10.2 CTNNB1 ERBB2 MTOR NFE2L2 PIK3CA PTEN
12 neoplasm MP:0002006 10.18 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
13 nervous system MP:0003631 10.18 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
14 adipose tissue MP:0005375 10.14 GNAS MTOR NFE2L2 PIK3CA PTEN STAT3
15 muscle MP:0005369 10.09 CTNNB1 ERBB2 GNAS MTOR PIK3CA PTEN
16 normal MP:0002873 10.03 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
17 limbs/digits/tail MP:0005371 10 CTNNB1 ERBB2 FGFR3 GNAS PTEN SMAD4
18 no phenotypic analysis MP:0003012 9.87 CTNNB1 FGFR3 GNAS HRAS MTOR PIK3CA
19 renal/urinary system MP:0005367 9.85 CTNNB1 FGFR3 GNAS HRAS MTOR NFE2L2
20 respiratory system MP:0005388 9.7 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
21 skeleton MP:0005390 9.44 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
Sources

Drugs & Therapeutics for Cervical Cancer

About this section

PubMed Health treatment related to Cervical Cancer: 62

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization ) might be enough. If the tumor has already spread to the surrounding tissue , doctors usually recommend having surgery to remove the entire womb (a hysterectomy ). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy .

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 443)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bethanechol Approved Phase 4 674-38-4 2370
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
6
Polihexanide Approved, Investigational Phase 4 28757-47-3
7
Meperidine Approved Phase 4 57-42-1 4058
8
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
9
Cantharidin Approved, Investigational Phase 4 56-25-7
10
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
11
Ferrous fumarate Approved Phase 4 141-01-5
12
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
13
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
14 Muscarinic Agonists Phase 4
15 Monophosphoryl lipid A Phase 4
16 Hypoglycemic Agents Phase 4
17 Contraceptive Agents Phase 4
18 Nicotinic Agonists Phase 4
19 Cholinergic Agents Phase 4
20 Epoetin alfa Phase 4 113427-24-0
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Dopamine Uptake Inhibitors Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Dopamine Agents Phase 4
26 Antidepressive Agents Phase 4
27 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
28 Autoantibodies Phase 4
29 Disinfectants Phase 4
30 Biguanides Phase 4
31 Calamus Phase 4
32 Progestins Phase 4
33
Medroxyprogesterone Phase 4 520-85-4 10631
34 Fluorodeoxyglucose F18 Phase 4
35 Nutrients Phase 4
36 Trace Elements Phase 4
37 Micronutrients Phase 4
38 Vitamins Phase 4
39 Immunologic Factors Phase 4
40 Vaccines Phase 4
41
leucovorin Approved Phase 3 58-05-9 6006 143
42
Hydralazine Approved Phase 3 86-54-4 3637
43
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
44
Fluspirilene Approved, Investigational Phase 3 1841-19-6 3396
45
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
46
Vinblastine Approved Phase 3 865-21-4 13342 241903
47
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
48
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
49
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
50
Granisetron Approved, Investigational Phase 3 109889-09-0 3510

Interventional clinical trials:

(show top 50) (show all 1503)
# Name Status NCT ID Phase Drugs
1 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
2 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
3 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
4 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
5 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
6 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
7 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
8 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
9 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
10 Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany Completed NCT02296255 Phase 4
11 Work Package 4: HPV Vaccination of Women in Screening Ages Completed NCT02837926 Phase 4
12 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
13 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
14 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
15 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
18 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
19 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
20 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
21 Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
22 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
23 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
24 Safety and Immunogenicity of Cervarixâ„¢ in Human Immunodeficiency Virus Infected Females Completed NCT01031069 Phase 4
25 Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru Completed NCT00925288 Phase 4
26 Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
27 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
28 Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial Completed NCT02684942 Phase 4 Meperidine;Fentanyl
29 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
30 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
31 Effectiveness of Home Based Distribution of Hormonal Contraceptives for Women at Risk for Unintended Pregnancy Completed NCT00928538 Phase 4
32 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
33 Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity Recruiting NCT03451071 Phase 4 Gardasil9
34 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Recruiting NCT03423082 Phase 4 18F fluciclovine
35 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Recruiting NCT03349463 Phase 4 Fluciclovine F18
36 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
37 Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening Active, not recruiting NCT01895517 Phase 4
38 Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
39 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
40 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
41 KENya Single-dose HPV-vaccine Efficacy - The KEN-SHE Study Enrolling by invitation NCT03675256 Phase 4
42 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
43 A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
44 Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
45 Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients Unknown status NCT00122746 Phase 3
46 Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
47 Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
48 Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
49 Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin（DDP） weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
50 A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image Unknown status NCT00146458 Phase 3

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

About this section
Sources

Anatomical Context for Cervical Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

19
Cervix

MalaCards organs/tissues related to Cervical Cancer:

40
Cervix, Testes, Breast, Lymph Node, T Cells, Uterus, Lung
Sources

Publications for Cervical Cancer

About this section

Articles related to Cervical Cancer:

(show top 50) (show all 30289)
# Title Authors PMID Year
1
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 54 61 56 6
1349102 1992
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 56 6
10471491 1999
3
Somatic LKB1 mutations promote cervical cancer progression. 54 61 56
19340305 2009
4
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. 61 56
23266353 2013
5
Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study. 61 42
31577720 2019
6
Landscape of genomic alterations in cervical carcinomas. 56
24390348 2014
7
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. 61 46
19859982 2009
8
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. 61 46
19682430 2009
9
Patterns of known and novel small RNAs in human cervical cancer. 61 46
17616659 2007
10
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 56
17360030 2007
11
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
12
Genetic link to cervical tumours. 56
10403244 1999
13
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 6
8589699 1995
14
Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. 56
8041728 1994
15
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 6
1849234 1991
16
A genetic model for colorectal tumorigenesis. 56
2188735 1990
17
Polymorphic variants conferring genetic risk to cervical lesions support GSTs as important associated loci. 42
31593112 2019
18
Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. 42
31638680 2019
19
HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. 54 61
20206160 2010
20
ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells. 54 61
20372863 2010
21
Analysis of expression and structure of the TSG101 gene in cervical cancer cells. 54 61
20372822 2010
22
DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells. 54 61
20442293 2010
23
Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). 54 61
19786613 2010
24
Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. 54 61
20167600 2010
25
Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. 54 61
20429915 2010
26
TP53, MDM2, NQO1, and susceptibility to cervical cancer. 54 61
20200430 2010
27
Oncosuppressor proteins of fragile sites are reduced in cervical cancer. 54 61
19700237 2010
28
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). 54 61
19816757 2010
29
Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. 54 61
20213048 2010
30
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. 54 61
20193846 2010
31
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. 54 61
19913895 2010
32
Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. 54 61
20015862 2010
33
Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women. 54 61
19730990 2010
34
Anti-angiogenesis agents in metastatic or recurrent cervical cancer. 54 61
19861227 2010
35
[Exploring the issue of cervical cancer prevention and control in women living with HIV/AIDS]. 54 61
20127625 2010
36
Gene promoter methylation patterns throughout the process of cervical carcinogenesis. 54 61
20208141 2010
37
Use of tissue microarray to facilitate oncology research. 54 61
20217582 2010
38
The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. 54 61
19949677 2009
39
[Mechanism of anti-tumor effect of HIF-1alpha silencing on cervical cancer in nude mice]. 54 61
20137345 2009
40
Novel ultrasound-targeted microbubble destruction mediated short hairpin RNA plasmid transfection targeting survivin inhibits gene expression and induces apoptosis of HeLa cells. 54 61
18991017 2009
41
Folate status and aberrant DNA methylation are associated with HPV infection and cervical pathogenesis. 54 61
19755648 2009
42
Tristetraprolin: a weapon against HPV-induced cervical cancer? 54 61
20157555 2009
43
Protective role of cytosolic 2-cys peroxiredoxin in the TNF-alpha-induced apoptotic death of human cancer cells. 54 61
19646526 2009
44
Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells. 54 61
19878546 2009
45
Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. 54 61
19574249 2009
46
Immunohistochemical expression of ubiquitin and telomerase in cervical cancer. 54 61
19680685 2009
47
The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. 54 61
20157568 2009
48
Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. 54 61
19672258 2009
49
HLA-G polymorphisms in women with squamous intraepithelial lesions harboring human papillomavirus. 54 61
19407850 2009
50
The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. 54 61
19820361 2009
Sources

Variations for Cervical Cancer

About this section

ClinVar genetic disease variations for Cervical Cancer:

6 (show top 50) (show all 142) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
2 SMAD4 NM_005359.5(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
3 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
4 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
5 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
6 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
7 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
8 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
9 FGFR3 NM_000142.4(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
10 FGFR3 NM_000142.4(FGFR3):c.1620C>G (p.Asn540Lys)SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
11 FGFR3 NM_000142.4(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
12 FGFR3 NM_000142.4(FGFR3):c.749C>G (p.Pro250Arg)SNV Pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
13 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
14 SMAD4 NM_005359.5(SMAD4):c.1082G>A (p.Arg361His)SNV Pathogenic 24832 rs377767347 18:48591919-48591919 18:51065549-51065549
15 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
16 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
17 FGFR3 NM_000142.4(FGFR3):c.1949A>C (p.Lys650Thr)SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
18 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
19 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
20 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
21 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
22 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
23 HRAS NM_005343.4(HRAS):c.436G>A (p.Ala146Thr)SNV Pathogenic/Likely pathogenic 12607 rs104894231 11:533467-533467 11:533467-533467
24 PIK3CA NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met)SNV Pathogenic/Likely pathogenic 376498 rs1057519942 3:178921548-178921548 3:179203760-179203760
25 ERBB2 NM_004448.3(ERBB2):c.2305G>C (p.Asp769His)SNV Pathogenic/Likely pathogenic 375991 rs121913468 17:37880261-37880261 17:39724008-39724008
26 ERBB2 NM_004448.3(ERBB2):c.2305G>T (p.Asp769Tyr)SNV Pathogenic/Likely pathogenic 375992 rs121913468 17:37880261-37880261 17:39724008-39724008
27 NFE2L2 NM_006164.5(NFE2L2):c.235G>A (p.Glu79Lys)SNV Pathogenic/Likely pathogenic 376466 rs1057519922 2:178098810-178098810 2:177234082-177234082
28 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr)SNV Pathogenic/Likely pathogenic 375894 rs121913403 3:41266113-41266113 3:41224622-41224622
29 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro)SNV Pathogenic/Likely pathogenic 375898 rs397517201 3:178936095-178936095 3:179218307-179218307
30 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
31 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu)SNV Pathogenic/Likely pathogenic 375899 rs397517201 3:178936095-178936095 3:179218307-179218307
32 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr)SNV Pathogenic/Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
33 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
34 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)SNV Pathogenic/Likely pathogenic 31944 rs121913273 3:178936082-178936082 3:179218294-179218294
35 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
36 GNAS NM_001077488.4(GNAS):c.604C>T (p.Arg202Cys)SNV Pathogenic/Likely pathogenic 15933 rs11554273 20:57484420-57484420 20:58909365-58909365
37 GNAS NM_001077488.4(GNAS):c.605G>A (p.Arg202His)SNV Pathogenic/Likely pathogenic 15934 rs121913495 20:57484421-57484421 20:58909366-58909366
38 GNAS NM_001077488.4(GNAS):c.605G>T (p.Arg202Leu)SNV Pathogenic/Likely pathogenic 210045 rs121913495 20:57484421-57484421 20:58909366-58909366
39 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
40 CTNNB1 NM_001904.4(CTNNB1):c.95A>G (p.Asp32Gly)SNV Pathogenic/Likely pathogenic 17578 rs121913396 3:41266098-41266098 3:41224607-41224607
41 CTNNB1 NM_001904.4(CTNNB1):c.110C>G (p.Ser37Cys)SNV Pathogenic/Likely pathogenic 17579 rs121913403 3:41266113-41266113 3:41224622-41224622
42 CTNNB1 NM_001904.4(CTNNB1):c.94G>T (p.Asp32Tyr)SNV Pathogenic/Likely pathogenic 17581 rs28931588 3:41266097-41266097 3:41224606-41224606
43 CTNNB1 NM_001904.4(CTNNB1):c.110C>T (p.Ser37Phe)SNV Pathogenic/Likely pathogenic 17586 rs121913403 3:41266113-41266113 3:41224622-41224622
44 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)SNV Pathogenic/Likely pathogenic 13654 rs121913286 3:178936094-178936094 3:179218306-179218306
45 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
46 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
47 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys)SNV Pathogenic/Likely pathogenic 13657 rs121913286 3:178936094-178936094 3:179218306-179218306
48 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp)SNV Pathogenic/Likely pathogenic 156446 rs587777790 3:178917478-178917478 3:179199690-179199690
49 MTOR NM_004958.4(MTOR):c.6644C>T (p.Ser2215Phe)SNV Pathogenic/Likely pathogenic 156703 rs587777894 1:11184573-11184573 1:11124516-11124516
50 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss HNT Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss INT2 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POUF3 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion LKB1 Cervical Cancer
35 124598 19 1156797 1179434 Deletion LKB1 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification C20orf20 Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain AIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer
Sources

Expression for Cervical Cancer

About this section
Search GEO for disease gene expression data for Cervical Cancer.
Sources

Pathways for Cervical Cancer

About this section

Pathways related to Cervical Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.92 TP53 STAT3 SMAD4 PTEN MTOR HRAS
2
TGF-Beta Pathway 63
Show member pathways
 13.63 TP53 STAT3 SMAD4 PIK3CA MTOR HRAS
3
Akt Signaling 63
Show member pathways
 13.51 TP53 STAT3 PTEN MTOR HRAS GNAS
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.43 TP53 STAT3 PIK3CA HRAS FGFR3 ERBB2
5
IL-2 Pathway 63
Show member pathways
 13.31 TP53 STAT3 PTEN MTOR HRAS GNAS
6
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.23 TP53 STAT3 SMAD4 PIK3CA HRAS GNAS
7
GAB1 signalosome 65
Show member pathways
 13.19 TP53 PTEN PIK3CA MTOR FGFR3 ERBB2
8
Phospholipase-C Pathway 63
Show member pathways
 13.14 TP53 PTEN MTOR HRAS GNAS FGFR3
9
Human cytomegalovirus infection 36
Show member pathways
 13.06 TP53 STAT3 PIK3CA MTOR HRAS GNAS
10
TNFR1 Pathway 63
Show member pathways
 13.03 TP53 PTEN PIK3CA MTOR HRAS CTNNB1
11
PI3K-Akt signaling pathway 36
Show member pathways
 13.03 TP53 PTEN PIK3CA MTOR HRAS GNAS
12
Focal Adhesion 1 36
Show member pathways
 13.02 STAT3 PTEN PIK3CA HRAS ERBB2 CTNNB1
13
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13 STAT3 PTEN PIK3CA MTOR HRAS ERBB2
14
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13 STAT3 PTEN PIK3CA MTOR HRAS GNAS
15
Endometrial cancer 36
Show member pathways
 12.9 TP53 STAT3 SMAD4 PTEN PIK3CA MTOR
16
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.88 STAT3 PTEN PIK3CA MTOR HRAS CCND1
17
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.86 TP53 PTEN PIK3CA MTOR HRAS FGFR3
18
Development HGF signaling pathway 22
Show member pathways
 12.82 TP53 STAT3 PTEN PIK3CA MTOR HRAS
19
Ras signaling pathway 36
Show member pathways
 12.81 PIK3CA HRAS GNAS FGFR3 CTNNB1
20
Gastric cancer 36
Show member pathways
 12.77 TP53 SMAD4 PTEN PIK3CA NFE2L2 MTOR
21
Relaxin signaling pathway 36
Show member pathways
 12.76 STAT3 PIK3CA MTOR HRAS GNAS
22
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.76 PIK3CA MTOR HRAS GNAS CTNNB1 CCND1
23
Glioma 36
Show member pathways
 12.73 TP53 STAT3 PTEN PIK3CA MTOR HRAS
24
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 TP53 STAT3 PIK3CA HRAS ERBB2 CTNNB1
25
T cell receptor signaling pathway 36
Show member pathways
 12.7 STAT3 PTEN PIK3CA MTOR HRAS
26
ErbB signaling pathway 1 36
Show member pathways
 12.64 TP53 STAT3 PTEN PIK3CA MTOR HRAS
27
mTOR signaling pathway (KEGG) 64
Show member pathways
 12.63 TP53 PTEN PIK3CA MTOR HRAS FGFR3
28
Development ERBB-family signaling 22
Show member pathways
 12.62 TP53 STAT3 PIK3CA MTOR HRAS ERBB2
29
Prolactin Signaling Pathway 1 36
Show member pathways
 12.61 STAT3 PTEN PIK3CA MTOR HRAS ERBB2
30
Apoptosis Pathway 70
Show member pathways
 12.56 TP53 PIK3CA MTOR HRAS FGFR3 ERBB2
31
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.54 TP53 PIK3CA MTOR HRAS CCND1
32
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.52 STAT3 PIK3CA MTOR HRAS FGFR3 ERBB2
33
Development IGF-1 receptor signaling 22
Show member pathways
 12.5 TP53 STAT3 PTEN PIK3CA MTOR HRAS
34
Human T-cell leukemia virus 1 infection 36
12.49 TP53 SMAD4 PTEN PIK3CA HRAS CCND1
35
Phospholipase D signaling pathway 36
Show member pathways
 12.47 PIK3CA MTOR HRAS GNAS
36
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.47 STAT3 PIK3CA HRAS CTNNB1
37
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.47 STAT3 PIK3CA MTOR HRAS CCND1
38
Development A3 receptor signaling 22
Show member pathways
 12.44 STAT3 PIK3CA HRAS CTNNB1 CCND1
39
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.44 PIK3CA HRAS GNAS ERBB2 CCND1
40
Viral carcinogenesis 36
12.41 TP53 STAT3 PIK3CA HRAS CCND1
41
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.4 PTEN PIK3CA MTOR HRAS
42
Colorectal Cancer Metastasis 63
12.34 TP53 STAT3 SMAD4 GNAS CTNNB1 CCND1
43
Cellular senescence (KEGG) 36
12.32 TP53 PTEN PIK3CA MTOR HRAS CCND1
44
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.31 TP53 STAT3 MTOR HRAS
45
EGF/EGFR Signaling Pathway 1
12.31 STAT3 PTEN MTOR HRAS ERBB2
46
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.31 TP53 PTEN PIK3CA MTOR HRAS FGFR3
47
Integrated Breast Cancer Pathway 1
12.29 TP53 SMAD4 PTEN MTOR CTNNB1 CCND1
48
mTOR Pathway 70
Show member pathways
 12.27 TP53 PIK3CA MTOR HRAS
49
Kit receptor signaling pathway 1
Show member pathways
 12.27 STAT3 PTEN PIK3CA HRAS
50
Development EGFR signaling via small GTPases 22
Show member pathways
 12.27 STAT3 PTEN PIK3CA HRAS GNAS ERBB2
Sources

GO Terms for Cervical Cancer

About this section

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.92 TP53 STAT3 SMAD4 CTNNB1

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.96 TP53 PTEN ERBB2 CTNNB1
2 negative regulation of gene expression GO:0010629 9.95 TP53 MIR214 MIR21 HRAS CTNNB1
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 PTEN MIR21 HRAS FGFR3
4 regulation of cell proliferation GO:0042127 9.91 TP53 STAT3 SMAD4 CTNNB1
5 cell proliferation GO:0008283 9.88 TP53 STAT3 SMAD4 PTEN CTNNB1
6 regulation of cell cycle GO:0051726 9.86 TP53 STAT3 PTEN CCND1
7 response to drug GO:0042493 9.85 TP53 STAT3 PTEN GNAS CTNNB1 CCND1
8 response to ethanol GO:0045471 9.84 TP53 STAT3 PTEN CCND1
9 positive regulation of MAPK cascade GO:0043410 9.83 HRAS FGFR3 ERBB2 CTNNB1
10 positive regulation of protein phosphorylation GO:0001934 9.83 MTOR MIR21 HRAS ERBB2 CCND1
11 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.81 SMAD4 PTEN MIR21
12 negative regulation of cell death GO:0060548 9.81 STAT3 SMAD4 NFE2L2
13 response to estradiol GO:0032355 9.8 STAT3 PTEN CTNNB1 CCND1
14 positive regulation of protein kinase B signaling GO:0051897 9.8 PIK3CA MTOR MIR21 FGFR3 ERBB2
15 positive regulation of epithelial cell proliferation GO:0050679 9.77 HRAS ERBB2 CCND1
16 positive regulation of osteoblast differentiation GO:0045669 9.77 MIR21 GNAS CTNNB1
17 positive regulation of cell proliferation GO:0008284 9.76 STAT3 PTEN MIR21 HRAS FGFR3 ERBB2
18 cell aging GO:0007569 9.69 TP53 MTOR HRAS
19 regulation of mitochondrial membrane permeability GO:0046902 9.66 TP53 STAT3
20 anoikis GO:0043276 9.65 PIK3CA MTOR
21 negative regulation of cell size GO:0045792 9.65 PTEN MTOR
22 response to leptin GO:0044321 9.65 STAT3 CCND1
23 cellular response to hypoxia GO:0071456 9.65 TP53 PTEN NFE2L2 MTOR MIR214
24 cellular response to leptin stimulus GO:0044320 9.64 STAT3 PTEN
25 positive regulation of metalloendopeptidase activity GO:1904685 9.63 STAT3 MIR21
26 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.63 NFE2L2 MIR214 MIR21
27 endothelial tube morphogenesis GO:0061154 9.62 MIR21 CTNNB1
28 positive regulation of epithelial to mesenchymal transition GO:0010718 9.62 SMAD4 MTOR MIR21 CTNNB1
29 mitotic G1 DNA damage checkpoint GO:0031571 9.61 TP53 CCND1
30 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.58 TP53 NFE2L2
31 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.58 TP53 NFE2L2
32 hair follicle placode formation GO:0060789 9.57 GNAS CTNNB1
33 negative regulation of cell proliferation GO:0008285 9.56 TP53 STAT3 SMAD4 PTEN MIR214 MIR21
34 positive regulation of gene expression GO:0010628 9.28 TP53 STAT3 PTEN NFE2L2 MTOR MIR21

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 TP53 STAT3 SMAD4 PTEN MTOR FGFR3
2 transcription regulatory region DNA binding GO:0044212 9.78 TP53 STAT3 SMAD4 NFE2L2
3 protein C-terminus binding GO:0008022 9.67 TP53 HRAS ERBB2 CTNNB1
4 RNA polymerase II transcription factor binding GO:0001085 9.58 TP53 SMAD4 CTNNB1
5 transcription factor binding GO:0008134 9.55 TP53 STAT3 NFE2L2 CTNNB1 CCND1
6 I-SMAD binding GO:0070411 9.46 SMAD4 CTNNB1
7 RNA polymerase II activating transcription factor binding GO:0001102 9.43 TP53 NFE2L2 CTNNB1
8 protein kinase binding GO:0019901 9.43 TP53 STAT3 PTEN MTOR CTNNB1 CCND1
9 transcription cofactor binding GO:0001221 9.32 TP53 NFE2L2
10 protein phosphatase binding GO:0019903 8.92 TP53 STAT3 ERBB2 CTNNB1
Sources

Sources for Cervical Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....